The Acute Liver Failure Study Group Initiates Phase 2a Study of OCR-002 for ... Sacramento Bee SAN DIEGO, Nov. 8, 2012 -- /PRNewswire/ -- Ocera Therapeutics, Inc. announced that the first patient has enrolled in a Phase 2a study to evaluate the safety and tolerability of OCR-002 (ornithine phenylacetate) in the treatment of patients with acute ... |
